iKang shrugs off China weakness to price healthy IPO

By Clare Hammond
10 Apr 2014

Beijing-based iKang Healthcare Group priced its $153m Nasdaq listing at the top of the range this week, as investors jumped at the chance to gain exposure to one of the fastest growing industries in China.

The deal priced on April 8 in the US, at $14 per share, the top of a $12-$14 range. The transaction comprised 10.9m American Depositary Shares — with every two ADSs representing one of iKang’s ordinary shares.

“It was a very good final book, highly oversubscribed, with more ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial